Biotech Big Bangs Its Way Into New York City Via Beacon Capital’s Incubator


Biotech Big Bangs Its Way Into New York City Via Beacon Capital’s Incubator

PR Newswire

NEW YORK, March 20, 2018 /PRNewswire/ — Beacon Capital released the introduction of a unique NYC incubator initiative “Beacon Pharma.” The Incubator will provide seed funding office, lab and manufacturing space for Life Science companies seeking JV and licensing partnerships to further develop their IP. Beacon Pharma will have 50,000 square feet of flex office and lab space in NY and NJ. The incubator/seed fund will place $30 million to $50 million into various startups selected by Beacon Pharma, as well as others in the New York and New Jersey area. According to Beacon Capital CEO, Nancy Torres Kaufman, Beacon is considering to launch similar initiatives in Virginia, Florida, and Mexico in the upcoming year. “Bringing the focus back is the reason why we decided to invest in biotech. Beacon Capital’s goal is to be a catalyst in minimizing drug to market time, while helping biotech companies remain well funded,” said Nancy Torres Kaufman.

The Beacon Pharma seed fund will be backed by Beacon Capital and its group of families as well as other unspecified strategic and life science investors. The size of investment per startup will be between $30,000 to $1 Million, structured mainly as convertible debt. Tenants at our facilities in NY and NJ will have access to seed funds; lab space, and manufacturing. We are currently reviewing applications for all companies interested in exploring our incubator structure. For more information please contact

Our goal is to make it affordable for biotech startups of modest financial means. We hope to support the tri-state community of biotech microcap companies. We feel this is an area where we could truly make a difference. Our focus expands into novel and bioequivalent IP in oncology, neurodegenerative, and rare diseases therapeutics.

Media contact:
Tobi Rubinstein


Cision View original content with multimedia:

SOURCE Beacon Capital Incubator Fund

MJ Biotech Inc. Announces Joint Venture with Florida’s

CHEYENNE, Wyo., March 20, 2018 (GLOBE NEWSWIRE) — MJ Biotech, Inc. (FKA Michael James Enterprises, Inc.) (OTC:MJTV) announced that it executed a Joint Venture agreement with Marijuana located in Florida to provide CBD Teas manufactured by Zen’s Tea House. The CBD Teas will be sold at all the Marijuana Doctors Florida locations. was founded as the trusted gateway for patients searching for medical marijuana treatment in legal medical marijuana states. We provide patients visibility and transparency in selecting a doctor and setting an appointment for a medical marijuana evaluation including detailed profile information, scheduling information, and ratings and reviews. We understand the uncertainty associated with the process and that medical marijuana is often the only effective treatment for many ailments for which traditional medicine provides little relief or is accompanied by uncomfortable and dangerous side effects.

Conference Call update.

The Conference call update will be delayed due to the most recent Joint Venture agreement. The new date will be announced this week.

Due to the new Joint Venture agreement if there are additional questions regarding this Press Release please send them to

Also Fernando Lopez the COO of MJ Biotech and President of Zen Tea House just did a new face book live with a Certified Holistic Nutritionist (FNS, CNPM, CHNP) about the benefits of teas & nutrition. This video can be seen at Facebook at

Additional information is available on the company’s websites,  and 

Safe Harbor Statement

This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “will,” “expects,” and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether because of new information, future events or any other reason.

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Fernando Lopez

Primary Logo

Boston Celtics Announce Partnership with G2 Tech Group

Boston Celtics Announce Partnership with G2 Tech Group

Celtics, G2 Tech Group to continue collaborating on team’s information management needs

PR Newswire

BOSTON, March 20, 2018 /PRNewswire/ – The Boston Celtics announced today their partnership with G2 Tech Group. The partnership will allow G2, who has been a team vendor for several years, to further assist the Celtics organization in its ever-increasing cloud infrastructure needs.

“G2 and its team of experts has been an exceptional vendor, one that has both fulfilled and anticipated our needs, and elevating this relationship to the partner level will allow us to work in even deeper collaboration,” said Celtics Vice President and Chief Technology Officer Jay Wessland. “Speed and reliability are of the utmost importance to our business, and they are without peer in these critical areas.”

G2 guided the Celtics’ initial forays into the cloud and has since helped the organization develop a robust and secure cloud computing environment, with unique high-performance computing resources available to support the Celtics’ operations. In addition to strategic consulting and implementation support, G2 provides 24/7 monitoring of infrastructure, which includes provisions for near-seamless disaster recovery in the event of a network outage.

G2 Tech Group serves as an Amazon Web Services Advanced Consulting Partner, specializing in cloud migrations, strategic managed cloud services, DevOps automation and cost optimization for growing companies.

“The Celtics have been a case study in effectively leveraging the power of the cloud to get better information in less time,” said G2 CEO and Chief Visionary Glenn Grant. “Now, as their partner, we’re looking forward to continuing to help the organization gain competitive advantages, both on and off the court.”

Cision View original content:

SOURCE G2 Tech Group